Revenues grew 8% to Rs.1595 crore in Q2FY24 compared to Rs 1475 crore last year. The earnings before interest, tax, depreciation and amortization (EBITA) declined 6% YoY to Rs 218 crore. The EBITDA margins stood at 14% in Q2FY24.
Indian drug company Dr Reddy s plans to use its net cash surplus of INR 5,000 crore ($670m) to fund acquisitions and innovations aiming at India, the US and emerging markets. CEO Erez Israeli said the funds would be used for product-acquiring licences, and added that the company
National Payments Corporation of India (NPCI) suggested imposing an interchange fee on transactions using the Unified Payments Interface (UPI) starting on April 1.